Patents
Literature
23 results about "Guanylate cyclase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Guanylate cyclase (EC 4.6.1.2, also known as guanyl cyclase, guanylyl cyclase, or GC) is a lyase enzyme. Guanylate cyclase is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylate cyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. Like cAMP, cGMP is an important second messenger that internalizes the message carried by intercellular messengers such as peptide hormones and nitric oxide, and can also function as an autocrine signal. Depending on cell type, it can drive adaptive/developmental changes requiring protein synthesis. In smooth muscle, cGMP is the signal for relaxation, and is coupled to many homeostatic mechanisms including regulation of vasodilation, vocal tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation, depending on the tissue.
Genetically engineered bacteria for synthesizing natural cyclic diguanosine monophosphate in large quantities and application thereof
This invention discloses a genetically engineered bacterium capable of synthesizing large quantities of natural cyclic diguanylate (c-di-GMP) and its applications. It involves knocking out the major phosphodiesterase gene chr1_233 as described in claim 1 within the sphingobium xenophagum C2 strain. This invention rationally designs and modifies the c-di-GMP synthesis and degradation pathways and the inhibitory site of major diguanylate cyclase activity in heterologous sphingobium-consuming bacteria, constructing a series of genetically engineered bacteria capable of synthesizing large quantities of natural c-di-GMP. This provides the industry with a green, simple, economical, and efficient method for producing natural c-di-GMP, and offers a series of high-quality and inexpensive raw materials for the preparation of STING agonists or immune adjuvants, or for the preparation of drugs for treating diseases related to STING protein function.
Owner:GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY
Combinations of GLP-1 and guanylate cyclase c (GC-c) receptor agonists
The present disclosure provides combinations of GLP-1 receptor agonists, and guanylate-cyclase C (GC-C) receptor agonists, and pharmaceutical compositions comprising the same. Also described are methods of making and using the combination, which can be used to treat or prevent of one or more side effects of a GLP-1 receptor agonist.
Owner:IRONWOOD PHARMACEUTICALS INC
Guanylate cyclase-c activator peptide and uses thereof
This invention discloses a guanylate cyclase-C (GC-C) activating peptide and its applications, belonging to the field of bioactive peptide technology. The amino acid sequence of the GC-C activating peptide is PFPGPIPN. The GC-C activating peptide of this invention can significantly activate GC-C activity, increasing intracellular cGMP levels. Furthermore, the GC-C activating peptide of this invention can alleviate constipation and abdominal pain symptoms in mice, thereby effectively preventing or improving irritable bowel syndrome (IBS). Therefore, the GC-C activating peptide provided by this invention has advantages such as high activity, safety and non-toxicity, and good water solubility. It can be used as a candidate molecule for alternative or adjuvant drugs in the clinical treatment of IBS, and also as a health product or food to improve constipation or abdominal pain.
Owner:NORTHWEST A & F UNIV +1
Pharmaceutical composition comprising a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain fatty acid or prodrug thereof
A pharmaceutical composition includes a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain C2 to C5 fatty acid and / or a salt and / or a prodrug thereof in a therapeutically effective amount and one or more pharmaceutically acceptable excipients as well as to a method of preventing and / or treating colorectal tumorigenesis and / or carcinogenesis and / or chronic intestinal inflammation and / or cystic fibrosis related gastrointestinal manifestations by administering to a patient, who has developed or is at risk to develop colorectal tumorigenesis and / or carcinogenesis and / or chronic intestinal inflammation and / or cystic fibrosis related gastrointestinal manifestations, a therapeutically effective amount of a combination of a GUCY2C agonist and a short-chain C2 to C5 fatty acid or a salt or a prodrug thereof.
Owner:OCVIRK SOREN
Treatment of mitochondrial diseases with a CNS-penetrant sgc stimulator zagociguat
The present invention relates to a method of treating a mitochondrial disease in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination therapy.
Owner:TISENTO THERAPEUTICS INC
Treatment of mitochondrial disorders with sGC stimulators
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof, and pharmaceutical preparations or dosage forms containing them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases, in which increased sGC stimulation, or increased concentrations of nitric oxide (NO) or cyclic guanosine 3',5'-monophosphate (cGMP), or both, or upregulation of the NO-sGC-cGMP pathway is desired. Compounds useful in the methods of the present invention are of Formula I or pharmaceutically acceptable salts thereof:
Owner:ティセント セラピューティクス インコーポレーテッド
Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy
PendingUS20260055209A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyCyclaseAntigen receptor
The present disclosure describes compositions and methods of treating solid tumors using chimeric antigen receptor (CAR) T cell (CAR-T) therapy and / or antibodies targeting uanylate Cyclase 2C (GCC. GUCY2C). The compositions include CAR comprising an extracellular domain that binds GCC. Further disclosed are methods of using modified T ceils expressing a CAR that binds GCC for treating different types of carters.
Owner:INNOVATIVE CELLULAR THERAPEUTICS HLDG LTD +1
Pyrimidine SGC stimulators
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof, and pharmaceutical formulations containing them, and their uses, alone or in combination with one or more additional agents, for treating various diseases in which an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic guanosine monophosphate (cGMP), or both, or upregulation of the NO pathway, is desired. In some embodiments, the compound is of Formula I or a pharmaceutically acceptable salt thereof. (I) TIFF2025536343000075.tif3865
Owner:ティセント セラピューティクス インコーポレーテッド
Prophylactic and therapeutic methods for managing diarrhea associated with cell therapy
Methods and compositions relate to managing chimeric antigen receptor T (CAR T) cell therapy-associated diarrhea in human subjects undergoing such therapy for colorectal cancer (CRC) are disclosed. The CAR T cells target a CRC-associated antigen, such as Guanylate Cyclase C (GCC) or Carcinoembryonic Antigen (CEA). The methods comprise administering a prophylactic regimen to the subject post-infusion of CAR T cells. This regimen includes agents such as vedolizumab, infliximab, or prophylactic budesonide. Subjects are monitored for diarrhea development and severity based on predefined clinical criteria, including stool frequency or stool volume. The methods may further involve a tiered therapeutic algorithm for treating occurring diarrhea, potentially utilizing corticosteroids or antithymocyte globulin (ATG). These approaches aim to reduce the incidence, duration, and severity of CAR T induced diarrhea, thereby improving patient safety and treatment tolerability.
Owner:INNOVATIVE CELLULAR THERAPEUTICS HLDG LTD +1
Inhalable pharmaceutical composition containing soluble guanylate cyclase receptor agonist, use thereof, and treatment method for pulmonary hypertension
An inhalable pharmaceutical composition containing a soluble guanylate cyclase (SGC) receptor agonist, and a use thereof. The present invention can reduce the hypotensive side effects caused during administration, allows blood pressure to rapidly return to a normal level after administration, and enables the SGC receptor agonist to enter blood more quickly, improving pharmacokinetic parameters such as Tmax; and under specific formulations and instrument combinations, a pulmonary deposition rate can reach 40% or above.
Owner:PRISETREE INTELLIGENT DRUGS INC
Methods and materials for treating chronic heart disorders
PCT designated stageWO2026080202A1Peptide/protein ingredientsPhosphorus-oxygen lyasesCyclaseChronic heart disease
Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH +1
TREATMENT OF MITOCHONDRIAL DISEASES WITH sGC STIMULATORS
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are those of Formula I or pharmaceutically acceptable salts thereof.
Owner:TISENTO THERAPEUTICS INC
Quercetin pill for reducing hypertension by improving vascular endothelial function
The invention discloses a quercetin pill for reducing hypertension by improving the vascular endothelial function, and relates to the technical field of quercetin pharmaceutical preparations. Comprising quercetin, eucommia ulmoides extract, hydroxypropyl-beta-cyclodextrin and hydroxypropyl methylcellulose. The quercetin pill can be used for preparing medicines for preventing and / or treating vascular endothelial dysfunction related cardiovascular diseases, especially hypertension closely related to a vascular endothelial injury mechanism. Quercetin promotes synthesis and release of nitric oxide of vascular endothelial cells, and NO is a powerful vasodilator and can diffuse to vascular smooth muscle cells, activate guanylate cyclase and increase cyclic guanosine monophosphate in the cells, so that the vascular smooth muscles are relaxed, blood vessels are expanded, and the vascular endothelial function is improved. In addition, quercetin can inhibit expression of inflammatory adhesion molecules and recruitment of inflammatory cells, so that inflammatory response of vascular endothelium is relieved. The problem that the use of quercetin in the aspect of reducing hypertension is limited in the prior art is solved.
Owner:SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
USE OF SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
Owner:CYCLERION THERAPEUTICS INC
Methods and materials for treating skeletal disorders
Methods and materials for treating skeletal disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) as a therapeutic agent for the treatment of skeletal disorders (e.g., achondroplasia) are provided herein.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH +1
Inhalable pharmaceutical composition containing soluble guanylate cyclase receptor stimulant and application thereof
The invention relates to the technical field of medicines, in particular to an inhalable pharmaceutical composition containing a soluble guanylate cyclase (SGC) receptor stimulant and application of the inhalable pharmaceutical composition, and clinical adverse reactions of medicines can be remarkably reduced. According to the pharmaceutical composition, the administration dosage is reduced, on the premise that the drug effect is kept unchanged, the hypotension side effect caused in the administration process is reduced, and the normal blood pressure level is rapidly recovered after administration. The pharmaceutical composition provided by the invention needs to be combined with matched instruments for use, wherein the pharmaceutical composition comprises an SGC receptor stimulant drug and other inhalable pharmaceutic adjuvants. The lung deposition rate can reach more than 40% under the combination of a specific prescription and instruments. Through inhalation of the pharmaceutical composition, an SGC receptor stimulant can enter blood more quickly, and pharmacokinetic parameters such as Tmax are improved.
Owner:PRISETREE INTELLIGENT DRUGS INC
RAAV-GUANYLATE CYCLASE COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBER'S CONGENITAL AMAUROSE-1 (LCA1)
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC
Fused bicyclic sgc stimulators
The present invention relates to fused bicyclic sGC stimulators. More specifically, the present invention relates to stimulators of the soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their use, alone or in combination with one or more other agents, for the treatment of various diseases, wherein for the treatment of said diseases it is desirable to increase the concentration of nitric oxide (NO) or to increase the concentration of cyclic guanosine monophosphate (cGMP) or to increase the concentration of both or to upregulate the NO-pathway. The compounds have the formula I:
Owner:TISENTO THERAPEUTICS INC
Heterocyclic carboxylic acid derivative, preparation method therefor, and pharmaceutical application thereof
Provided are a heterocyclic carboxylic acid derivative, a preparation method therefor, and a pharmaceutical application thereof. Specifically, provided are a heterocyclic carboxylic acid derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as an sGC (soluble guanylate cyclase) agonist and / or activator, and the use thereof in the preparation of a drug for treating and / or preventing diseases responsive to sGC agonists and / or activators.
Owner:SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD
DEUTERATED sGC STIMULATORS
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8 and Y9 is independently selected from hydrogen and deuterium, as well as pharmaceutical compositions, methods and uses thereof.
Owner:TISENTO THERAPEUTICS INC
Diguanylate cyclase variants and methods of their use
The present invention provides light-responsive polypeptides having diguanylate cyclase (DGC) activity, nucleic acid molecules encoding such polypeptides, host cells comprising such polypeptides or nucleic acid molecules, compositions, and methods of their use. More particularly, the present invention provides a NIR light-responsive DGC polypeptide variant with increased enzymatic activity and sensitivity to NIR light compared to its parental polypeptide to allow more dynamic control of intracellular c-di-GMP dynamics with various in vitro and in vivo applications.
Owner:NANYANG TECH UNIV +1
Anti-GCC antibodies, chimeric antigen receptors and uses thereof
The invention belongs to the field of biological medicine, and relates to an anti-GCC (guanylate cyclase C) antibody or antigen binding fragment, a chimeric antigen receptor (CAR) containing the anti-GCC antibody or antigen binding fragment and application. The disclosed anti-GCC antibodies or antigen-binding fragments can be used in companion diagnosis of GCC-related diseases or disorders, such as immunohistochemical assays; the disclosed immune cells transduced by the GCC CAR constructs can be used in cellular immunotherapy of GCC-related diseases or conditions.
Owner:NANJING LEGEND BIOTECH CO LTD
Pyrimidine sgc stimulators
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an uregulation of the NO pathway is desirable. In some embodiments, the compounds are those of Formula I or a pharmaceutically acceptable salt thereof. (I)
Owner:TISENTO THERAPEUTICS INC